

# Index

## Pharmacological Reviews

Volume 32

1980

- Adenosine, role in control of renin release, 128  
Adenosine 3',5'-monophosphate, cyclic, role in renin release, 126  
Adenylate cyclase  
  dopamine-sensitive  
    dopamine cogeners on  $\alpha_1$  sites (table), 237  
    inhibition by neuroleptics, 236  
Adrenergic agonists,  $\beta$ -, role in renin release, 144  
Adrenergic antagonists  
   $\alpha$ -, effect on renin release, 141  
   $\beta$ -, role in renin release, 144  
Adrenergic receptors  
   $\alpha$ -, role, in renin release, 100  
  labeled by  $^3\text{H}$ -neuroleptics, 256  
Adrenergic receptor agonists,  $\alpha$ -, effects on renin release, 133  
Adrenergic receptor blocking activity,  $\alpha$ -, drugs with, 143  
Adrenergic receptor blocking drugs,  $\beta$ -, renin release alteration by (table), 145  
Adrenoceptors, presynaptic, development of subsensitivity of, 347  
Adrenoceptors,  $\alpha$ -presynaptic  
  and postsynaptic, differences between, that mediate response of effector organ, 341  
  influence of neuronal uptake of norepinephrine on negative feedback mechanism mediated by, 345  
  inhibitory  
    and membrane  $\text{Na}^+\text{-K}^+$  in norepinephrine release, 341  
    and regulation of noradrenergic neurotransmission, 338  
    presence in central nervous system, 346  
  significance of negative feedback mechanism mediated by, 347  
Adrenoceptors,  $\alpha_1$ -  
   $^3\text{H}$ -clonidine binding to, in rat submaxillary gland (table), 344  
   $^3\text{H}$ -prazosin binding to, in rat cerebral cortex membranes (table), 344  
Adrenoceptors,  $\alpha_1$ - and  $\alpha_2$ -  
  distribution and physiological effects mediated by (table), 343  
  in central nervous system (fig.), 346  
  localisation of, by binding studies, 344  
  postsynaptic, in vascular smooth muscle (fig.), 343  
  relative orders of potency of agonists and antagonists for (table), 342  
Adrenoceptors,  $\alpha_3$ , involvement in presynaptic modulation of release of epinephrine in central nervous system, 354  
Adrenoceptors,  $\alpha$ - and  $\beta$ -, presynaptic, on peripheral noradrenergic nerve terminals (fig.), 339  
Adrenoceptors,  $\beta$ , presynaptic facilitatory, in peripheral noradrenergic nerve endings, 348  
Adrenocorticotrophic hormone, effects on renin release, 197  
Agonist  
   $^3\text{H}$ -, inhibition of binding  
    to anterior pituitary (table), 285  
    to brain striatum (table), 251  
Alkaline phosphatase, role of changes in, on vitamin D action, 67  
Alzheimer's disease, choline or lecithin administration for, 327  
Amiloride, effects on renin release, 171  
Androgens, effects on renin release, 189  
Anesthetics, effects on renin release, 129; (table), 130  
Angiotensin, effects on renin release, 117  
Angiotensin I, inhibitors of converting enzyme of, effect on renin release, 177  
Angiotensin II  
  antagonists of, effect on renin release, 172  
  brief description of, 85  
  pharmacology of, 85  
Antidiuretic hormone, effects on renin release, 119  
Anti-inflammatory drugs, nonsteroidal, effect on renin release, 181  
Apomorphine  
   $^3\text{H}$ -, binding conditions (table), 260  
  pre- and postsynaptic action of, 274  
Appetite control, tryptophan administration for, 329  
Arginine vasopressin, effects on renin release, 119  
Ataxia, choline or lecithin administration for, 328  
Autonomic nervous system  
  drugs affecting, 133  
  role, in renin release, 93  
Barabé, J. See Regoli and Barabé, 1  
Baroreceptor, intrarenal, 86  
Behavioral effects of neurotransmitter precursors, 325  
Bone  
  cells of, and their putative roles, 50  
  formation and mineralization, 48  
  formation and resorption, 48  
  interrelationships, 50  
  resorption, 49  
  responses, evaluation of, 51  
  vitamin D  
    actions on, unsolved questions, 66  
    and, 47  
    effects on mineralization in, 61  
    effects on resorption of, 64  
Bradykinin  
  concentration-response curves (fig.), 17  
  concentration-response curves of, in vascular preparations containing receptor  $\text{B}_1$  and receptor  $\text{B}_2$  (fig.), 22  
  des-Arg<sup>9</sup>-, structure-activity relationship of, and its derivatives, on  $\text{B}_1$  receptor system, 25  
  structure and biological activities of (table), 26  
  history, 2  
  [Leu-OMe<sup>8</sup>], des-Arg<sup>9</sup>-, specificity of inhibitory action of (table), 28  
  -like material, concentration of, in plasma and biological fluids of normal subjects and patients affected by various diseases (table), 9  
  primary structure of, and site of action of proteolytic enzymes (fig.), 4  
  radioligand assays for, 34  
  related kinins and, pharmacology of, 1  
  relative potency of, in pharmacological preparations; effects of antagonists (table), 22  
  responsiveness of isolated blood vessels to (table), 13  
  structure-activity relationships of its homologues, fragments, and analogues on the  $\text{B}_2$  receptor system, 28  
Brain dopamine receptors, 229  
  development and aging of, hyperactivity syndrome, 284  
Brain serotonin synthesis and release, food consumption, plasma amino acid levels and, relationships between (fig.), 318  
Bretylium, effects on renin release, 156

- Bromocriptine, pre- and postsynaptic action of, 275  
 Bumetanide, effect on renin release, 159  
 Butaclamol, stereoselectivity on  $^3\text{H}$ -ligand binding to tissues (table), 243
- Calcium, role, in renin release, 112  
 Campbell, William B. See Keeton and Campbell, 81  
 Carbonic anhydrase inhibitors, effects on renin release, 169  
 Cardiac glycosides, effects on renin release, 158  
 Cardiovascular system, biological actions of kinins associated with, 10  
 Catalepsy, neuroleptic-induced, 232  
 Catecholamines  
   effects on renin release *in vitro*, 100  
   endogenous, drugs that affect, 155  
   increased circulating levels of, effect on renin release, 97  
   neuronal, inhibitors of uptake of, 156  
   presynaptic regulation of the release of, 337
- Central nervous system  
    $\alpha_1$ - and  $\alpha_2$ -adrenoceptors in (fig.), 346  
    $\alpha_2$ -adrenoceptor involvement in presynaptic modulation of release of epinephrine in, 354  
   presence of presynaptic inhibitory  $\alpha$ -adrenoceptors in, 346
- Chlorthalidone, effects on renin release, 171  
 Choline  
   Alzheimer's disease, 327  
   ataxia, 328  
   Huntington's disease, 327  
   myasthenic syndrome, 328  
   psychiatric disorders, 328  
   tardive dyskinesia, 327  
   Tourette's syndrome, 328
- Cholinergic antagonists, effects on renin release, 157  
 Clonidine  
    $^3\text{H}$ -, binding to  $\alpha_2$ -adrenoceptors in rat submaxillary gland (table), 344  
   effects on renin release, 134
- Cloпамide, effects on renin release, 171  
 Collagen synthesis, effect of vitamin D on, 66  
 Contraceptives, oral, effects on renin release, 190  
 Cyclic nucleotides, involvement of, in presynaptic inhibition of norepinephrine release, 340
- Depression, tryptophan for, 328  
 Diazoxide, effects on renin release, 195  
 Diuretics  
   loop, effects on renin release, 159  
   mercurial, effects on renin release, 169  
   minor, effects on renin release, 172  
   non-"loop," effects on renin release, 169  
   osmotic, effect on renin release, 169
- L-Dopa  
   effects on renin release, 138  
   suppression of renin release, 138  
   holidays, rehypersensitization of  $\text{D}_2$  transmission, 278
- Dopamine  
    $^3\text{H}$ -, binding to  $\text{D}_3$  sites in calf,  $\text{IC}_{50}$  values (fig.), 258  
   electrophysiological action, 231  
   negative feedback regulation of release of, through presynaptic inhibitory dopamine receptors, 352  
   neuroleptic blockade of neurophysiological action of, 232  
   neuroleptics and, conformational fit between, 233  
   -related compounds, structures of (fig.), 267  
   -sensitive adenylate cyclase, dopamine congeners on  $\text{D}_1$  sites (table), 237  
   -sensitive sites and receptors, terminology for (fig.), 231  
   structural fit with neuroleptics (Dreiding models) (fig.), 231
- Dopamine agonists  
   at  $\text{D}_2$  receptor, structural requirements for, 267  
   acting on the  $\text{D}_2$  dopamine receptor, structure-activity data (figs.), 269, 270, 271  
   correlation of autoreceptor actions of, with effects on  $\text{D}_3$  dopamine sites (fig.), 276  
   effects of, on reversal of elevated  $\text{D}_2$  receptors, 283  
   inhibition of prolactin release from pituitary cells (fig.), 286  
   pre- and postsynaptic action of, 275
- Dopamine autoreceptors, possible relation to binding sites for dopaminergic  $^3\text{H}$ -ligands, 273  
 Dopamine congeners on  $\text{D}_1$  sites (table), 237  
 Dopamine hypothesis of schizophrenia, neuroleptics and, 233  
 Dopamine-mimetic drug action, neuroleptic blockade of, 232  
 Dopamine neurones  
   lesions of  
     in adult rats, 274  
     in immature rats, 274  
     in Parkinson's disease, 274
- Dopamine receptors  
   brain, 229  
     development and aging of, hyperactivity syndrome, 284  
     effects of lesions on (table), 264  
     effect of long-term drugs on (table), 281  
      $^3\text{H}$ -ligands for, 239; (table), 240  
     *in vivo* analysis of, 239  
     in peripheral tissues, 275  
     in pituitary and peripheral tissues, 285  
     in postmortem brains of schizophrenics (table), 282  
     neuroleptic action on, 232  
     neuroleptic-induced dopaminergic supersensitivity and, 280  
     presynaptic inhibitory  
       in peripheral noradrenergic nerve endings, 349  
       negative feedback regulation of release of dopamine through, 352  
     renal, femoral, and brain (table), 287  
     terminology for, 230
- Dopamine-sensitive adenylate cyclase, 255  
   inhibition of, by neuroleptics, 236
- Dopamine sensitivity  
   density of  $\text{D}_2$  receptors and, relation between, 282  
    $\text{D}_2$  receptors, role of estrogen, and, 283
- Dopamine turnover, 232  
 Dopaminergic agonist  $^3\text{H}$ -ligands, binding properties of, 257  
 Dopaminergic  $^3\text{H}$ -ligands  
   correlations between behaviour and binding of, 265  
   nonstriatal tissues, receptor density ( $B_{\text{max}}$ ) and  $K_D$  for (table), 242  
   relation of dopamine autoreceptors to binding sites for, 273  
   striatum, receptor density ( $B_{\text{max}}$ ) and  $K_D$  for (table), 241
- Dopaminergic  $^3\text{H}$ -ligand binding, effects of ions and nucleotides on, 265  
 Dopaminergic nerve endings, central, presynaptic receptor systems on, 353  
 Dopaminergic neurones, dopaminergic supersensitivity after denervation of, 280  
 Dopaminergic receptors, labeled by  $^3\text{H}$ -neuroleptics, 256  
 Dopaminergic supersensitivity  
   after denervation of dopamine neurones, 280  
   after neuroleptic administration, 279  
   behavioural, after long-term neuroleptics, 280  
   biochemical and electrophysiological aspects of, 280  
   neuroleptic-induced, dopamine receptors and, 280
- Epinephrine,  $\alpha_2$ -adrenoceptors involvement in presynaptic modulation of release of, in central nervous system, 354  
 Estrogens  
   antidopaminergic action of, 283  
   effects on renin release, 186  
 Ethacrynic acid, effects on renin release, 159  
 Exocrine glands, biological actions of kinins in, 15
- Food consumption, plasma amino acid levels, and brain serotonin synthesis and release, relationships between (fig.), 318  
 Furosemide, effects on renin release, 159

- Galactorrhea, neuroleptic-induced, 232
- Ganglionic stimulants, effect on renin release, 157
- Glucagon, effect on renin release, 199
- Glucocorticoids, effect on renin release, 188
- Growth hormone, effects on renin release, 198
- Guanethidine, effects on renin release, 156
- Hefti, F. *See* Wurtman et al., 315
- Huntington's disease, choline or lecithin administration for, 327
- Hydralazine, effects on renin release, 191
- 6-Hydroxydopamine, effects on renin release, 156
- 5-Hydroxytryptamine, effects on renin release, 125
- Hyperactivity syndrome, development and aging of brain dopamine receptors, 284
- Hyperprolactinemia, neuroleptic-induced, 232
- Inflammation, biological actions of kinins in, 14
- Insulin, effects on renin release, 200
- Kallidin**  
concentration-response curves (fig.), 17  
primary structure of, and site of action of proteolytic enzymes (fig.), 4
- Kallikrein-kinin system**, 3  
components of, in biological fluids, 5
- Kallikreins**, actions of, 15
- Keeton, T. Kent, and William B. Campbell. The pharmacologic alteration of renin release, 81
- Kinins**  
action mechanism of, 34  
activation of, 3  
antagonists of, on B<sub>2</sub> receptor systems, 32  
antagonists that block effects of, on B<sub>1</sub> receptor system (table), 27  
biological actions of, 10  
bradykinin and related kinins, pharmacology of, 1  
cardiovascular system, regulation of, 10  
exocrine glands, actions in, 15  
formation and breakdown, 3  
history, 1  
inactivation of, 3  
inflammation, role in, 14  
pharmacological and metabolic features of (table), 37  
pharmacological preparations, 16  
potentiation of pharmacological effects produced by, 33  
properties, comparison of (table), 7  
receptors for, 20  
receptors mediating the contractile or relaxing effects of, in isolated smooth muscle preparations (table), 21  
structure-activity studies, response (table), 19  
structure and biological activities of (table), 26
- Langer, S. Z. Presynaptic regulation of the release of catecholamines, 337
- Lecithin**  
Alzheimer's disease, 327  
ataxia, 328  
Huntington's disease, 327  
myasthenic syndrome, 328  
psychiatric disorders, 328  
tardive dyskinesia, 327  
Tourette's syndrome, 328
- Lithium, effects on renin release, 180
- Magnesium, effects on renin release, 116
- Melamed, E. *See* Wurtman et al., 315
- Metabolism, renal sodium, and the macula densa segment of the distal tubule, 102
- Metaraminol effects on renin release, 139
- Methoxamine, inhibition of renin release, 139
- Methyldopa, suppression of renin release, 137
- Metolazone, effects on renin release, 171
- Mineralocorticoids, effect on renin release, 186
- Minoxidil, effects on renin release, 193
- Muscarinic antagonists, effect on renin release, 158
- Muscarinic receptors, presynaptic inhibitory, in peripheral noradrenergic nerve endings, 350
- Myasthenic syndrome, choline or lecithin administration for, 328
- Myoclonus, posthypoxic intention, tryptophan administration, 329
- Nerve impulses, neuroleptic block of, 235
- Neuroendocrine effects of neurotransmitter precursors, 325
- Neuroleptic**  
early supersensitivity after single dose of, 280  
<sup>3</sup>H-, binding properties, correlates of, 244  
inhibition of binding to anterior pituitary (table), 285  
-induced catalepsy and Parkinsonism, 232  
-induced dopaminergic supersensitivity, dopamine receptors and, 280  
-induced galactorrhea, 232  
-induced hyperprolactinemia, 232
- Neuroleptic action**  
nanomolar concentration criterion for specific, 233  
nonreceptor sites of, 234  
on dopamine receptors, 232  
receptor sites for, 236  
stereoselective, criterion of, 234
- Neuroleptic block**  
of nerve impulses, 235  
of transmitter uptake, 236  
presynaptic autoreceptors and presynaptic coupling, 235
- Neuroleptic blockade**  
dopamine-mimetic drug action, 232  
neurophysiological action of dopamine, 232
- Neuroleptic/serotonin receptors (S<sub>2</sub>)**, sites in cerebral cortex (table), 255
- Neuroleptic sites of action**, criteria for, 233
- Neuroleptics**  
dopamine and, conformational fit between, 233  
dopamine hypothesis of schizophrenia and, 233  
disinhibition of tyrosine hydroxylase by, 236  
dopaminergic supersensitivity after administration of, 279  
<sup>3</sup>H-, dopaminergic, serotonergic, and adrenergic receptors labeled by, 256  
sites labeled by, 250  
inhibition of dopamine-sensitive adenylate cyclase by, 236  
inhibition of <sup>3</sup>H-neuroleptic binding to brain striatum by (table), 245  
in serum, use of D<sub>2</sub> receptors for measuring, 277  
long-term, behavioural dopaminergic supersensitivity after, 280  
partition coefficients of (table), 234  
pre- and postsynaptic action of, 275  
range and average clinical dose for controlling schizophrenia (fig.), 238  
sensitivities of various sites to (table), 235  
spontaneous release and membrane fluidization by, 236  
tardive dyskinesia, 279
- Neurologic diseases**  
decreased number of synapses, 324  
decreased transmitter release, 324
- Neurons**  
components of positive feedback loops, 322  
lacking multisynaptic feedback loops, 322  
release of variable quantities of neurotransmitter per firing without engaging feedback responses, 323  
subjected to sustained increases in firing frequency, physiologic situations, 323
- Neurotransmission**  
enhanced by precursor administration, in neurodegenerative diseases (fig.), 324  
precursor availability and, 322

- Neurotransmitter precursor  
 availability, 316  
 behavioral effects of, 325  
 blood-brain barrier mechanisms mediating transport of (fig.), 317  
 choline, 327  
 clinical applications of, 327  
 neuroendocrine effects of, 325  
 tryptophan, 328  
 tyrosine, 329
- Neurotransmitter synthesis  
 mechanisms coupling intraneuronal precursor levels to, 320  
 precursor control of, 315
- Nicotinic antagonists, effects on renin release, 157
- Noradrenergic nerve endings  
 peripheral and central, presynaptic inhibitory opiate receptors in, 351  
 peripheral  
 presynaptic facilitatory  $\beta$ -adrenoceptors in, 348  
 presynaptic inhibitory dopamine receptors in, 349  
 presynaptic inhibitory muscarinic receptors in, 350  
 presynaptic receptors on, 352
- Noradrenergic neurotransmission  
 presynaptic inhibition of, by prostaglandins, 351  
 presynaptic inhibitory  $\alpha$ -adrenoceptors and regulation of, 338
- Norepinephrine, neuronal uptake of, influence on negative feedback mechanism mediated by presynaptic  $\alpha$ -adrenoceptors, 345
- Norepinephrine release  
 cyclic nucleotides in presynaptic inhibition of, 340  
 membrane  $\text{Na}^+\text{-K}^+$  ATPase in modulation of, through presynaptic inhibitory  $\alpha$ -adrenoceptors, 341
- Opiate receptors, presynaptic, in peripheral and central noradrenergic nerve endings, 351
- Parkinsonism  
 neuroleptic-induced, 232
- Parkinson's disease  
 D<sub>2</sub> receptors and, 278  
 lesions of dopamine neurones in, 274
- Parasympathetic nervous system, effects on renin release, 102
- Parathyroid hormone, effects on renin release, 200
- Peripheral tissues, dopamine receptors in, 285
- Phenoxybenzamine, effects on renin release, 141
- Phentolamine, effects on renin release, 141
- Phenylephrine, effects on renin release, 139
- Phosphodiesterase inhibitors, role in renin release, 153
- Pituitary tissues, dopamine receptors in, 285
- Plasma amino acid levels, food consumption, brain serotonin synthesis and release and, relationships between (fig.), 318
- Plasma renin activity, total, alteration by physiologic and pharmacologic interventions (table), 202
- Plasma (serum) renin activity, measurement of, 85
- Plasma (serum) renin concentration, measurement of, 85
- Potassium, effects on renin release, 109
- Prazosin, <sup>3</sup>H-, binding to  $\alpha_1$ -adrenoceptors in rat cerebral cortex membranes (table), 344
- Prazosin, effects on renin release, 143
- Precursor control of neurotransmitter synthesis, 315
- Progestins, effect on renin release, 190
- Prostaglandins  
 presynaptic inhibition of noradrenergic neurotransmission by, 351  
 role in control of renin release, 122  
 synthesis inhibitors, effect on renin release, 181
- Psychiatric disorders, choline or lecithin administration for, 328
- role in physiopathology, 23  
 preparations containing (table), 24
- Receptor B<sub>1</sub> system  
 antagonists that block effects of kinins (table), 27  
 structure-activity relationship of des-Arg<sup>9</sup>-bradykinin and its derivatives, on, 25
- Receptor B<sub>2</sub>, preparations containing (table), 24
- Receptor B<sub>2</sub> systems  
 antagonists of kinins on, 32  
 kinins, fragments, and analogues in (table), 30  
 structure-activity relationship of bradykinin, its homologues, fragments, and analogues on, 28
- Receptor D<sub>1</sub> sites and D<sub>2</sub> receptors, differences between, 261
- Receptors D<sub>2</sub>  
 binding properties of <sup>3</sup>H-ligands to, 240  
 density of, relation to dopamine sensitivity, 282  
 dopamine agonist at, structural requirements for, 267  
 dopamine sensitivity, role of estrogen and, 283  
 IC<sub>50</sub> values on <sup>3</sup>H-agonist and <sup>3</sup>H-antagonist binding to (table), 240  
 Parkinson's disease and, 278  
 reversal of elevated, effects of dopamine agonists, 283  
 schizophrenia and, 278  
 transmission, L-dopa holidays and rehypersensitization of, 278  
 use, for measuring neuroleptics in serum, 277
- Receptors D<sub>2</sub> and D<sub>3</sub> sites  
 distinction between, 260  
 localization of, 272
- Receptors  
 dopamine, 229  
 presynaptic  
 on peripheral noradrenergic nerve endings, 352  
 therapeutic potential, 354
- Receptor systems, presynaptic, on central dopaminergic nerve endings, 353
- Regoli, D., and J. Barabé. Pharmacology of bradykinin and related kinins, 1
- Renin  
 active, alteration by physiologic and pharmacologic interventions (table), 202  
 brief description, 84  
 inactive  
 alteration by physiologic and pharmacologic interventions (table), 202  
 and its alteration by drugs, 202
- Renin-angiotensin system, inhibitors of, role in experimental and clinical hypertension, 172
- Renin release  
 alteration of, by  $\beta$ -adrenergic receptor blocking drugs (table), 145  
 anatomical relationship of granular juxtaglomerular cells, afferent arteriole, renal sympathetic nerves, and macula densa cells of the distal tubule (fig.), 84  
 autonomic nervous system, role of, 93  
 calcium, role of, 112  
 effects of  
 $\alpha$ -adrenergic antagonists, 141  
 $\alpha$ -adrenergic receptor agonists, 133  
 adrenocorticotrophic hormone, 197  
 amiloride, 171  
 androgens, 189  
 anesthetics, 129; (table), 130  
 antagonists of angiotensin II, 172  
 antidiuretic hormone, 119  
 arginine vasopressin on, 119  
 bretylium, 156  
 bumetanide, 159  
 carbonic anhydrase inhibitors, 169  
 cardiac glycosides, 158  
 catecholamines on, in vitro, 100  
 chlorthalidone, 171
- Receptor B<sub>1</sub>  
 de novo formation of (table), 24

- cholinergic antagonists, 157  
 clonidine, 134  
 clopamide, 171  
 diazoxide, 195  
 L-dopa, 138  
 estrogens, 186  
 ethacrynic acid, 159  
 furosemide, 159  
 ganglionic stimulants, 157  
 glucocorticoids, 188  
 growth hormone, 198  
 guanethidine, 156  
 6-hydroxydopamine, 156  
 increased circulating levels of catecholamines, 97  
 inhibitors of angiotensin I converting enzyme, 177  
 insulin, 200  
 lithium, 180  
 "loop" diuretics, 159  
 magnesium, 116  
 mercurial diuretics, 169  
 metaraminol, 139  
 methoxamine, 139  
 metolazone, 171  
 mineralocorticoids, 186  
 minor diuretics, 172  
 minoxidil, 193  
 muscarinic antagonists, 158  
 nicotinic antagonists, 157  
 non-"loop" diuretics, 169  
 nonsteroidal anti-inflammatory drugs (prostaglandin synthesis inhibitors), 181  
 oral contraceptives, 190  
 osmotic diuretics, 169  
 parathyroid hormone, 200  
 phenoxybenzamine, 141  
 phentolamine, 141  
 phenylephrine, 139  
 potassium, 109  
 prazosin, 143  
 progesterone, 190  
 reserpine, 155  
 serotonin (5-hydroxytryptamine), 125  
 sodium, 108  
 sodium nitroprusside, 196  
 somatostatin, 199  
 spironolactone, 171  
 steroids, 186  
 thiazides, 169  
 triamterene, 171  
 tyramine, 140  
 vasodilators, 191  
 juxtaglomerular apparatus, anatomy of, 83  
 pharmacologic alteration of, 81, 129  
 physiologic control of, 86  
 renal nerve stimulation, 93  
 role of  
   adenosine in control of, 128  
    $\beta$ -adrenergic antagonists and agonists, 144  
   cyclic adenosine 3',5'-monophosphate, 126  
   phosphodiesterase inhibitors, 153  
   prostaglandins in release of, 122  
   suppression of, by angiotensin, 117  
 Renin response to  $\alpha$ -adrenergic antagonists, importance of pre- and postjunctional  $\alpha$ -adrenergic antagonists, 143  
 Reserpine, effects on renin release, 155  
  
**Schizophrenia**  
   neuroleptics and the dopamine hypothesis of, 233  
   range and average dose of neuroleptics for control of (fig.), 238  
  
 Schizophrenics, dopamine receptors in postmortem brains of (table), 282  
 Seeman, Philip. Brain dopamine receptors, 229  
 Serotonergic receptors labeled by  $^3\text{H}$ -neuroleptics, 256  
 Serotonin, effects on renin release, 125  
 Sleep, tryptophan administration for, 329  
 Sodium, effects on renin release, 108  
 Sodium nitroprusside, effects on renin release, 196  
 Somatostatin, effects on renin release, 199  
 Siperone binding  
   to brain striatum homogenate,  $^3\text{H}$ -, typical results for drug inhibition of (fig.), 257  
   to rat brain tissue resolution of the dopaminergic and serotonergic components of (fig.), 256  
   to  $\text{D}_2$  and  $\text{S}_2$  receptors, resolution of (table), 257  
 Spironolactone, effects on renin release, 171  
 Stern, Paula H. The D vitamins and bone, 47  
 Steroids, effect on renin release, 186  
 Sympathetic nervous system  
   drugs that affect, 155  
   renal nerves, stimulation of, 93  
  
**Tardive dyskinesia**  
   choline or lecithin administration for, 327  
   neuroleptics and, 279  
 Thiazides, effect on renin release, 169  
 Tourette's syndrome, choline or lecithin administration for, 328  
 Triamterene, effects on renin release, 171  
 Tryptophan  
   appetite control, 329  
   depression, 328  
   posthypoxic intention myoclonus, 329  
   sleep, 329  
 Tryptophan levels  
   brain, relationship with serum tryptophan ratio (fig.), 317  
   plasma, relation to dietary protein content (fig.), 317  
 Tryptophan malabsorption, 329  
 Tyramine, effect on renin release, 140  
 Tyrosine, 329  
 Tyrosine hydroxylase, disinhibition of, by neuroleptics, 236  
  
**Vascular receptor, intrarenal, 86**  
**Vasodilators, effect on renin release, 191**  
**Vitamin D**  
   action of, role of changes in alkaline phosphatase, 67  
   actions on bone, unsolved questions, 66  
   analog studies (table), 57, 58  
   analogs, relative potencies of, on bone resorption and intestinal receptor binding (table), 59  
   basic structure (fig.), 52  
   biosynthesis, 52  
   bone and, 47  
   dual effects of, on bone, 61  
   effect on  
     collagen synthesis, 66  
     mineralization in bone, 61, 66  
     stimulation of bone resorption, 64  
   function of, in the body, 67  
   metabolism, 52  
     major pathways of (fig.), 55  
   pharmacokinetics, 55  
   structural characteristics, 52  
   synthetic analogs, 56  
 Vitamin  $\text{D}_3$  metabolites, relative potencies of, on bone function in vitro (table), 62  
  
 Wurtman, R. J., F. Hefti, and E. Melamed. Precursor control of neurotransmitter synthesis, 315

U.S. POSTAL SERVICE  
STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION  
*(Required by 39 U.S.C. 3685)*

1. TITLE OF PUBLICATION <b>PHARMACOLOGICAL REVIEWS</b>		A. PUBLICATION NO. 4 2 9 5 6 0		B. DATE OF FILING 10/1/80	
3. FREQUENCY OF ISSUE Quarterly		A. NO. OF ISSUES PUBLISHED ANNUALLY 4		B. ANNUAL SUBSCRIPTION PRICE \$20.00	
4. LOCATION OF KNOWN OFFICE OF PUBLICATION (Street, City, County, State and ZIP Code) (Not printers) 428 E. Preston Street, Baltimore, MD 21202					
5. LOCATION OF THE HEADQUARTERS OR GENERAL BUSINESS OFFICES OF THE PUBLISHERS (Not printers) 428 E. Preston Street, Baltimore, MD 21202					
6. NAMES AND COMPLETE ADDRESSES OF PUBLISHER, EDITOR, AND MANAGING EDITOR					
PUBLISHER (Name and Address) Williams & Wilkins Co., 428 E. Preston Street, Balto., MD 21202					
EDITOR (Name and Address) Dr. Paul W. Munson, School of Medicine, Univ. of N. Carolina					
MANAGING EDITOR (Name and Address) Chapel Hill, NC 27514					
7. OWNER (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated.)					
NAME ADDRESS American Society for Pharmacology and Experimental Therapeutics c/o Dr. Houston Baker 9650 Rockville Pike Bethesda, MD 20014					
8. KNOWN BONDHOLDERS, MORTGAGEES, AND OTHER SECURITY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF TOTAL AMOUNT OF BONDS, MORTGAGES OR OTHER SECURITIES (If none, so state)					
NAME ADDRESS None					
9. FOR COMPLETION BY NONPROFIT ORGANIZATIONS AUTHORIZED TO MAIL AT SPECIAL RATES (Section 132.123, PSN) The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (Check one)					
<input checked="" type="checkbox"/> HAVE NOT CHANGED DURING PRECEDING 12 MONTHS <input type="checkbox"/> HAVE CHANGED DURING PRECEDING 12 MONTHS (If changed, publisher must submit explanation of change with this statement.)					
B. EXTENT AND NATURE OF CIRCULATION		AVERAGE NO. COPIES EACH ISSUE DURING PRECEDING 12 MONTHS		ACTUAL NO. COPIES OF SINGLE ISSUE PUBLISHED NEAREST TO FILING DATE	
A. TOTAL NO. COPIES PRINTED (Net Press Run)		3895		3865	
B. PAID CIRCULATION 1. SALES THROUGH DEALERS AND CARRIERS, STREET VENDORS AND COUNTER SALES		None		None	
2. MAIL SUBSCRIPTIONS		3144		2787	
C. TOTAL PAID CIRCULATION (Sum of 1B1 and 1B2)		3144		2787	
D. FREE DISTRIBUTION BY MAIL, CARRIER OR OTHER MEANS SAMPLES, COMPLIMENTARY, AND OTHER FREE COPIES		45		27	
E. TOTAL DISTRIBUTION (Sum of C and D)		3189		2814	
F. COPIES NOT DISTRIBUTED 1. OFFICE USE, LEFT OVER, UNACCOUNTED, SPOILED AFTER PRINTING		706		1051	
2. RETURNS FROM NEWS AGENCIES		None		None	
G. TOTAL (Sum of E, F1 and F2—should equal net press run shown in A)		3895		3865	
11. I certify that the statements made by me above are correct and complete.		SIGNATURE AND TITLE OF EDITOR, PUBLISHER, BUSINESS MANAGER, OR OWNER <i>Laura B. Rhoads</i> -Publisher			
12. FOR COMPLETION BY PUBLISHERS MAILING AT THE REGULAR RATES (Section 132.121, Postal Service Manual) 39 U. S. C. 3626 provides in pertinent part: "No person who would have been entitled to mail matter under former section 4359 of this title shall mail such matter at the rates provided under this subsection unless he files annually with the Postal Service a written request for permission to mail matter at such rates." In accordance with the provisions of this statute, I hereby request permission to mail the publication named in item 1 at the phased postage rates presently authorized by 39 U. S. C. 3626.					
SIGNATURE AND TITLE OF EDITOR, PUBLISHER, BUSINESS MANAGER, OR OWNER <i>Laura B. Rhoads</i> -Publisher					